keyword
https://read.qxmd.com/read/38625053/regulation-of-the-function-of-t-follicular-helper-cells-and-b-cells-in-type-1-diabetes-mellitus-by-the-ox40-ox40l-axis
#1
JOURNAL ARTICLE
Xuan Du, Yan Zhu, Wen Lu, Nannan Fu, Qin Wang, Bimin Shi
OBJECTIVE/MAIN OUTCOME: To study the expression of OX40 on T follicular helper (Tfh) cells and the ligand OX40L on antigen-presenting cells (APCs) in peripheral blood of patients with Type 1 diabetes mellitus (T1DM) and the role of OX40 signaling in promoting Tfh cells to assist B-cell differentiation. DESIGN: Cross-sectional study. SETTING: Endocrinology department of a university hospital. PARTICIPANTS: Twenty-five patients with T1DM and 35 with newly diagnosed T2DM from January 2021-December 2021 (39 males, 21 females; mean age: 31...
April 16, 2024: Journal of Clinical Endocrinology and Metabolism
https://read.qxmd.com/read/38607026/an-ox-tra-ordinary-tale-the-role-of-ox40-and-ox40l-in-atopic-dermatitis
#2
REVIEW
Kaviyon Sadrolashrafi, Lily Guo, Robin Kikuchi, Audrey Hao, Rebecca K Yamamoto, Hannah C Tolson, Sara N Bilimoria, Danielle K Yee, April W Armstrong
The transmembrane glycoprotein OX40 receptor (OX40) and its ligand, OX40L, are instrumental modulators of the adaptive immune response in humans. OX40 functions as a costimulatory molecule that promotes T cell activation, differentiation, and survival through ligation with OX40L. T cells play an integral role in the pathogenesis of several inflammatory skin conditions, including atopic dermatitis (AD). In particular, T helper 2 (TH 2) cells strongly contribute to AD pathogenesis via the production of cytokines associated with type 2 inflammation (e...
March 28, 2024: Cells
https://read.qxmd.com/read/38540714/tnf-superfamily-and-ilc2-activation-in-asthma
#3
REVIEW
Takahiro Matsuyama, Brittany Marie Salter, Nahal Emami Fard, Kentaro Machida, Roma Sehmi
Eosinophilic asthma is the most prevalent and well-defined phenotype of asthma. Despite a majority of patients responding to corticosteroid therapy and T2 biologics, there remains a subset that have recurrent asthma exacerbations, highlighting a need for additional therapies to fully ameliorate airway eosinophilia. Group 2 innate lymphoid cells (ILC2) are considered key players in the pathogenesis of eosinophilic asthma through the production of copious amounts of type 2 cytokines, namely IL-5 and IL-13. ILC2 numbers are increased in the airways of asthmatics and with the greatest numbers of activated ILC2 detected in sputa from severe prednisone-dependent asthma with uncontrolled eosinophilia...
February 29, 2024: Biomolecules
https://read.qxmd.com/read/38526805/ox40-ox40-ligand-and-its-role-in-precision-immune-oncology
#4
REVIEW
Bicky Thapa, Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Suzanna Lee, Mary K Nesline, Rebecca A Previs, Jeffery M Conroy, Paul DePietro, Sarabjot Pabla, Razelle Kurzrock
Immune checkpoint inhibitors have changed the treatment landscape for various malignancies; however, their benefit is limited to a subset of patients. The immune machinery includes both mediators of suppression/immune evasion, such as PD-1, PD-L1, CTLA-4, and LAG-3, all of which can be inhibited by specific antibodies, and immune-stimulatory molecules, such as T-cell co-stimulatory receptors that belong to the tumor necrosis factor receptor superfamily (TNFRSF), including OX40 receptor (CD134; TNFRSF4), 4-1BB (CD137; TNFRSF9), and glucocorticoid-induced TNFR-related (GITR) protein (CD357; TNFRSF18)...
March 25, 2024: Cancer Metastasis Reviews
https://read.qxmd.com/read/38496859/association-of-ox40l-gene-polymorphism-with-multiple-sclerosis-in-iranians
#5
JOURNAL ARTICLE
Abdolreza Sotoodeh Jahromi, Saiedeh Erfanian, Abazar Roustazadeh
INTRODUCTION: The exact etiology of multiple sclerosis is unknown but recent studies indicated a link between tumor necrosis factor superfamily member 4 and the disease. Polymorphisms located in the regulatory region of the gene may affect its phenotype. Hence, we aimed to investigate the association of promoter polymorphisms of the gene with multiple sclerosis and also to estimate the frequency of haplotypes in the patients and healthy subjects. METHODS: Two hundred age- and sex-matched subjects including 100 patients and 100 healthy subjects were investigated in the study...
March 30, 2024: Heliyon
https://read.qxmd.com/read/38493950/plasmid-dna-ionisable-lipid-nanoparticles-as-non-inert-carriers-and-potent-immune-activators-for-cancer-immunotherapy
#6
JOURNAL ARTICLE
Yue Qin, Nadia Rouatbi, Julie Tzu-Wen Wang, Rafal Baker, James Spicer, Adam A Walters, Khuloud T Al-Jamal
Immunotherapy is currently a standard of care in the treatment of many malignancies. However, predictable side effects caused by systemic administration of highly immunostimulatory molecules have been a serious concern within this field. Intratumoural expression or silencing of immunogenic and immunoinhibitory molecules using nucleic acid-based approaches such as plasmid DNA (pDNA) and small interfering RNA (siRNA), respectively, could represent a next generation of cancer immunotherapy. Here, we employed lipid nanoparticles (LNPs) to deliver either non-specific pDNA and siRNA, or constructs targeting two prominent immunotherapeutic targets OX40L and indoleamine 2,3-dioxygenase-1 (IDO), to tumours in vivo...
March 15, 2024: Journal of Controlled Release
https://read.qxmd.com/read/38486421/retrospective-analyses-of-pd-l1-lag-3-tim-3-ox40l-expressions-and-msi-status-in-gastroenteropancreatic-neuroendocrine-neoplasms
#7
JOURNAL ARTICLE
Fatih Gürler, Selin Aktürk Esen, Bediz Kurt İnci, Osman Sütçüoğlu, Gökhan Uçar, Orhun Akdoğan, Doğan Uncu, Nesrin Turhan, Nalan Akyürek, Nuriye Özdemir, Ahmet Özet, Ozan Yazıcı
We investigated expressions of PD-L1, LAG-3, TIM-3, and OX40L as immune checkpoint proteins, and MSI (repetitive short-DNA-sequences due to defective DNA-repair system) status were analyzed with immunohistochemistry from tissue blocks. Of 83 patients, PD-L1 expression was observed in 18.1% (n = 15) of the patients. None of the patients exhibited LAG-3 expression. TIM-3 expression was 4.9% (n = 4), OX40L was 22.9% (n = 19), and 8.4% (n = 7) of the patients had MSI tumor...
March 14, 2024: Cancer Investigation
https://read.qxmd.com/read/38441354/virus-infected-mast-cells-activate-virus-specific-cd8-t-cells
#8
JOURNAL ARTICLE
Yana Hackler, Frank Siebenhaar, Marcus Maurer, Melba Muñoz
Efficient anti-viral responses of CD8+ T cells require signals that promote their effector cell differentiation, that are mainly provided by dendritic cells (DCs). Mast cells (MCs) are key drivers of DC maturation, but also influence their migration and antigen presenting properties and therefore indirectly mediate CD8+ T cell activation. MCs initiate innate immune responses at pathogen entry sites, promote the development of adaptive immune responses after infection, and release mediators including chemokines that recruit and activate immune cells including T cells during viral infections...
August 2023: Scandinavian Journal of Immunology
https://read.qxmd.com/read/38267413/tumour-retained-activated-ccr7-dendritic-cells-are-heterogeneous-and-regulate-local-anti-tumour-cytolytic-activity
#9
JOURNAL ARTICLE
Colin Y C Lee, Bethany C Kennedy, Nathan Richoz, Isaac Dean, Zewen K Tuong, Fabrina Gaspal, Zhi Li, Claire Willis, Tetsuo Hasegawa, Sarah K Whiteside, David A Posner, Gianluca Carlesso, Scott A Hammond, Simon J Dovedi, Rahul Roychoudhuri, David R Withers, Menna R Clatworthy
Tumour dendritic cells (DCs) internalise antigen and upregulate CCR7, which directs their migration to tumour-draining lymph nodes (dLN). CCR7 expression is coupled to an activation programme enriched in regulatory molecule expression, including PD-L1. However, the spatio-temporal dynamics of CCR7+ DCs in anti-tumour immune responses remain unclear. Here, we use photoconvertible mice to precisely track DC migration. We report that CCR7+ DCs are the dominant DC population that migrate to the dLN, but a subset remains tumour-resident despite CCR7 expression...
January 24, 2024: Nature Communications
https://read.qxmd.com/read/38236520/ox40-in-the-pathogenesis-of-atopic-dermatitis-a-new-therapeutic-target
#10
REVIEW
Michael Croft, Ehsanollah Esfandiari, Camilla Chong, Hailing Hsu, Kenji Kabashima, Greg Kricorian, Richard B Warren, Andreas Wollenberg, Emma Guttman-Yassky
Atopic dermatitis (AD) is a chronic, heterogeneous, inflammatory disease characterized by skin lesions, pruritus, and pain. Patients with moderate-to-severe AD experience chronic symptoms, intensified by unpredictable flares, and often have comorbidities and secondary complications, which can result in significant clinical burden that impacts the patient's overall quality of life. The complex interplay of immune dysregulation and skin barrier disruption drives AD pathogenesis, of which T-cell-dependent inflammation plays a critical role in patients with AD...
January 18, 2024: American Journal of Clinical Dermatology
https://read.qxmd.com/read/38223555/an-engineered-influenza-a-virus-expressing-the-co-stimulator-ox40l-as-an-oncolytic-agent-against-hepatocellular-carcinoma
#11
JOURNAL ARTICLE
Hao Yang, Guanglin Lei, Zhuoya Deng, Fang Sun, Yuying Tian, Jinxia Cheng, Hongyu Yu, Cong Li, Changqing Bai, Shaogeng Zhang, Guangwen An, Penghui Yang
BACKGROUND: Oncolytic virus (OV) therapy has emerged as a promising novel form of immunotherapy. Moreover, an increasing number of studies have shown that the therapeutic efficacy of OV can be further improved by arming OVs with immune-stimulating molecules. METHODS: In this study, we used reverse genetics to produce a novel influenza A virus, termed IAV-OX40L, which contained the immune-stimulating molecule OX40L gene in the influenza virus nonstructural (NS1) protein gene...
2024: Journal of Hepatocellular Carcinoma
https://read.qxmd.com/read/38213072/astragaloside-iv-targeting-autophagy-of-t-cells-improves-inflammation-of-asthma
#12
JOURNAL ARTICLE
Qing-Qing Yang, Hong-Ying Zhang, Xiao-Hong Duan, Mi-Hui Li, Jing Sun, Li-Xia Tian, Jing-Cheng Dong, Ling-Wen Kong
Astragaloside IV (AST) has been confirmed to have antiasthmatic effects. However, the underline mechanism is unclear. The study aimed to explore the treatment mechanism of AST based on autophagy of memory T cells. AST treatment significantly decreased the number of T effector cells in asthma mice blood and the nude mice that received AST-treated TCM s had relieved inflammation compared with the untreated group; meanwhile, we found that AST significantly decreased the autophagy level and inhibited OX40/OX40L signal pathway of lymphocytes...
January 11, 2024: Journal of Asian Natural Products Research
https://read.qxmd.com/read/38201837/the-potential-role-of-moringa-oleifera-lam-leaf-proteins-in-moringa-allergy-by-functionally-activating-murine-bone-marrow-derived-dendritic-cells-and-inducing-their-differentiation-toward-a-th2-polarizing-phenotype
#13
JOURNAL ARTICLE
Chuyu Xi, Wenjie Li, Xiaoxue Liu, Jing Xie, Shijun Li, Yang Tian, Shuang Song
Moringa oleifera leaves are an inexpensive substitute for staple foods. Despite limited data, Moringa oleifera leaf protein (Mo-Pr) may be allergenic in BALB/c mice. In mouse models and allergic patients, dendritic cells (DCs) may be involved in food allergy. In addition, some allergens, including food allergens, can directly activate DCs and induce Th2 polarization. We investigated whether Mo-Pr can modulate the functional profile of murine bone marrow-derived dendritic cells (BMDCs) in vitro. BMDCs were obtained from mouse bone marrow cultured with granulocyte-macrophage colony-stimulating factor (GM-CSF) for 7 days and then treated with lipopolysaccharide (LPS) or Mo-Pr...
December 19, 2023: Nutrients
https://read.qxmd.com/read/38186219/treatment-of-atopic-dermatitis-recently-approved-drugs-and-advanced-clinical-development-programs
#14
REVIEW
Svenja Müller, Laura Maintz, Thomas Bieber
Atopic dermatitis (AD) represents the most common skin disease characterized by heterogeneous endophenotypes and a high disease burden. In Europe, six new systemic therapies for AD have been approved: the biologics dupilumab (anti-interleukin-4 receptor (IL-4R) α in 2017), tralokinumab (anti-IL-13 in 2021), lebrikizumab (anti-IL-13 in 2023), and the oral janus kinase (JAK) inhibitors (JAKi) targeting JAK1/2 (baricitinib in 2020 in the EU) or JAK1 (upadacitinib in 2021 and abrocitinib in 2022). Herein, we give an update on new approvals, long-term safety, and efficacy...
January 8, 2024: Allergy
https://read.qxmd.com/read/38142184/differential-expression-of-immune-checkpoints-ox40-ox40l-and-pd-1-pd-l1-in-decidua-of-unexplained-recurrent-spontaneous-abortion-women
#15
JOURNAL ARTICLE
Chenyue Qian, Chenhuan Pan, Juanjuan Liu, Lijuan Wu, Jie Pan, Cuiping Liu, Hong Zhang
In this study, we aimed to investigate the expression of OX40, OX40L, PD-1 and PD-L1 in patients with unexplained recurrent spontaneous abortion (URSA) compared to normal pregnancies (NP). A total of 50 patients who were diagnosed with URSA and 41 NP were recruited to this study. Real-time polymerase chain reaction (RT-PCR) was used to determine the expression of OX40, OX40L, PD-1 and PD-L1 in decidual tissues; Immunohistochemistry (IHC) was conducted to characterize the distribution of the involved genes in decidual tissues; Double immunofluorescence staining was used to prove the localization of the involved genes in decidual tissues...
December 22, 2023: Human Immunology
https://read.qxmd.com/read/38140230/agonistic-bivalent-human-scfvs-fc%C3%AE-fusion-antibodies-to-ox40-ectodomain-enhance-t-cell-activities-against-cancer
#16
JOURNAL ARTICLE
Kodchakorn Mahasongkram, Kantaphon Glab-Ampai, Kanasap Kaewchim, Thanatsaran Saenlom, Monrat Chulanetra, Nitat Sookrung, Oytip Nathalang, Wanpen Chaicumpa
(1) Background: Understanding how advanced cancers evade host innate and adaptive immune opponents has led to cancer immunotherapy. Among several immunotherapeutic strategies, the reversal of immunosuppression mediated by regulatory T cells in the tumor microenvironment (TME) using blockers of immune-checkpoint signaling in effector T cells is the most successful treatment measure. Furthermore, agonists of T cell costimulatory molecules (CD40, 4-1BB, OX40) play an additional anti-cancer role to that of checkpoint blocking in combined therapy and serve also as adjuvant/neoadjuvant/induction therapy to conventional cancer treatments, such as tumor resection and radio- and chemo- therapies...
December 7, 2023: Vaccines
https://read.qxmd.com/read/38085145/amygdalin-improves-allergic-asthma-via-the-thymic-stromal-lymphopoietin-dendritic-cell-ox40-ligand-axis-in-a-mouse-model
#17
JOURNAL ARTICLE
Wen Cui, Huan Zhou, Ya-Zun Liu, Yan Yang, Yi-Zhong Hu, Zhao-Peng Han, Jian-Er Yu, Zheng Xue
Asthma, characterized by persistent inflammation and increased sensitivity of the airway, is the most common chronic condition among children. Novel, safe, and reliable treatment strategies are the focus of current research on pediatric asthma. Amygdalin, mainly present in bitter almonds, has anti-inflammatory and immunoregulatory potential, but its effect on asthma remains uninvestigated. Here, the impact of amygdalin on the thymic stromal lymphopoietin (TSLP)-dendritic cell (DC)-OX40L axis was investigated...
October 29, 2023: Iranian Journal of Allergy, Asthma, and Immunology
https://read.qxmd.com/read/38076896/activating-neutrophils-by-co-administration-of-immunogenic-recombinant-modified-vaccinia-virus-ankara-and-granulocyte-colony-stimulating-factor-for-the-treatment-of-malignant-peripheral-nerve-sheath-tumor
#18
Yueqi Wang, Shuaitong Liu, Juan Yan, Shanza Baseer-Tariq, Bharath Salla, Liangliang Ji, Ming Li, Ping Chi, Liang Deng
Malignant peripheral nerve sheath tumor (MPNST) is a rare, aggressive soft-tissue sarcoma with a poor prognosis and is insensitive to immune checkpoint blockade (ICB) therapy. Loss-of-function of the histone modifying polycomb repressive complex 2 (PRC2) components, EED or SUZ12, is one of the main mechanisms of malignant transformation. In a murine model of MPNST, PRC2-loss tumors have an "immune desert" phenotype and intratumoral (IT) delivery immunogenic modified vaccinia virus Ankara (MVA) sensitized the PRC2-loss tumors to ICB...
November 29, 2023: bioRxiv
https://read.qxmd.com/read/38040340/ox40l-expressing-m1-like-macrophage-exosomes-for-cancer-immunotherapy
#19
JOURNAL ARTICLE
Yongkang Yu, Tingxuan Li, Meitong Ou, Ran Luo, Hongzhong Chen, He Ren, Zimu Li, Jie Sun, Hanjie Zhang, Shaojun Peng, Yanli Zhao, Lin Mei
With only limited clinical patient benefit, focusing on new immune checkpoint pathways could be an important complement to current immune checkpoint drugs. In addition, not only does T cell-mediated adaptive immunity play an important role, but also macrophage-mediated innate immunity, due to its abundant presence in solid tumors. Here, we developed an engineered M1-like macrophage exosome, OX40L M1-exos. OX40L M1-exos can activate the adaptive immunity by activating the OX40/OX40L pathway and can reprogram M2-like tumor-associated macrophages into M1-like macrophages, thereby restoring and enhancing macrophage-mediated innate immunity...
December 2, 2023: Journal of Controlled Release
https://read.qxmd.com/read/37961535/engineered-immunomodulatory-extracellular-vesicles-derived-from-epithelial-cells-acquire-capacity-for-positive-and-negative-t-cell-co-stimulation-in-cancer-and-autoimmunity
#20
Fernanda G Kugeratski, Valerie S LeBleu, Dara P Dowlatshahi, Hikaru Sugimoto, Kent A Arian, Yibo Fan, Li Huang, Danielle Wells, Sergio Lilla, Kelly Hodge, Sara Zanivan, Kathleen M McAndrews, Raghu Kalluri
Extracellular vesicles (EVs) are generated by all cells and systemic administration of allogenic EVs derived from epithelial and mesenchymal cells have been shown to be safe, despite carrying an array of functional molecules, including thousands of proteins. To address whether epithelial cells derived EVs can be modified to acquire the capacity to induce immune response, we engineered 293T EVs to harbor the immunomodulatory CD80, OX40L and PD-L1 molecules. We demonstrated abundant levels of these proteins on the engineered cells and EVs...
November 4, 2023: bioRxiv
keyword
keyword
73534
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.